P. Schmucker

Ifosfamide and carboplatin combined with 41.8 degrees C whole-body hyperthermia in patients with refractory sarcoma and malignant teratoma.

M. Mentzel, M. Klouche, S. Feddersen, 1994, Cancer research.

Comparison of First-Line Anti-PD-1-Based Combination Therapies in Metastatic Renal-Cell Carcinoma: Real-World Experiences from a Retrospective, Multi-Institutional Cohort

P. Karakiewicz, J. Ellinger, C. Kalogirou, 2022, Urologia Internationalis.

MiR-205-driven downregulation of cholesterol biosynthesis through SQLE-inhibition identifies therapeutic vulnerability in aggressive prostate cancer

S. Wach, M. Eilers, M. Spahn, 2021, Nature Communications.

HGF-Induced PD-L1 Expression in Head and Neck Cancer: Preclinical and Clinical Findings

Jonas Teusch, U. Müller-Richter, M. Bittrich, 2020, International journal of molecular sciences.

C‐reactive protein flare‐response predicts long‐term efficacy to first‐line anti‐PD‐1‐based combination therapy in metastatic renal cell carcinoma

M. Eckstein, J. Ellinger, D. Sikic, 2021, Clinical & translational immunology.

First-line immune combination therapies for non-clear cell vs. clear cell metastatic renal cell carcinoma: Real-world multicenter data from Germany

C. Kalogirou, S. Banek, B. Hoeh, 2024, Clinical Genitourinary Cancer.

Early CRP kinetics to predict long‐term efficacy of first‐line immune‐checkpoint inhibition combination therapies in metastatic renal cell carcinoma: an updated multicentre real‐world experience applying different CRP kinetics definitions

C. Kalogirou, N. Klümper, A. Mattigk, 2023, Clinical & translational immunology.